Triethylamine → HCID 178511622, Verbindung

HRID 1943476

Reaktionsgleichung

Reaktionsgleichung von HRID 1943476
Cl[C:2]1[CH:3]=[C:4]([N:14](CC2C=CC(OC)=CC=2)[C:15]2[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=2)[C:5]2[N:6]([C:8]([C:11]([OH:13])=O)=[CH:9][N:10]=2)[N:7]=1.[F:30][C:31]1[CH:37]=[CH:36][C:34]([NH2:35])=[CH:33][CH:32]=1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.C(N(CC)CC)C.[NH2:66][C@H:67]1[CH2:72][CH2:71][C@H:70]([NH2:73])[CH2:69][CH2:68]1>C(Cl)Cl.O.C(#N)C>[NH2:66][C@H:67]1[CH2:72][CH2:71][C@H:70]([NH:73][C:2]2[CH:3]=[C:4]([NH:14][C:15]3[CH:16]=[CH:17][CH:18]=[CH:19][CH:20]=3)[C:5]3[N:6]([C:8]([C:11]([NH:35][C:34]4[CH:36]=[CH:37][C:31]([F:30])=[CH:32][CH:33]=4)=[O:13])=[CH:9][N:10]=3)[N:7]=2)[CH2:69][CH2:68]1

Komponenten

9

Versuchsvorschrift

In a 2 dram reaction vial containing acetonitrile (1 mL) at ambient temperature was added 6-chloro-8-((4-methoxybenzyl)(phenyl)amino)imidazo[1,2-b]pyridazine-3-carboxylic acid (0.025 g, 0.06 mmol), 4-fluoroaniline (0.010 g, 0.09 mmol), EDCI (0.018 g, 0.09 mmol), HOBt (0.012 g, 0.09 mmol), and triethylamine (0.025 mL, 0.18 mmol). The suspension was stirred overnight at room temperature. The reaction mixture was then concentrated in vacuo and the residue mixed with trans-1,4-diaminocyclohexane (0.5 g, 4.39 mmol) and heated to 160° C. for 5 h. After cooling to room temperature, the reaction mixture was diluted with DCM/water and the layers were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in DCM (1 mL) at room temperature and charged with TFA (1 mL). The mixture was stirred 3 h, whereupon the volatiles were removed via a stream of nitrogen and the crude mixture was purified via preparative HPLC (Waters Sunfire column 5u, 100 A°, 19×100 mm, 20-100% Solvent B, (Solvent A (90% water, 10% methanol, 0.1% TFA), Solvent B (10% water, 90% methanol, 0.1% TFA), 10 min gradient, 10 minute run, 25 mL/min)), affording the title compound, 6-((trans)-4-aminocyclohexylamino)-N-(4-fluorophenyl)-8-(phenylamino)imidazo[1,2-b]pyridazine-3-carboxamide (0.009 g, 22%). HPLC: Rt=3.04 min. (Waters sunfire 4.6×50 mm C18.5 um 4 min/1 min hold time 0-100% (A-B) A=10% MeOH-90% water-0.1% TFA, B=90% MeOH-10% water-0.1% TFA). MS: [M+H]=460.0.

Aufarbeitung

  1. customIn a 2 dram reaction
  2. concentrationThe reaction mixture was then concentrated in vacuo
  3. temperatureheated to 160° C. for 5 h
  4. temperatureAfter cooling to room temperature
  5. customthe layers were separated
  6. dry with materialThe organic phase was dried over anhydrous sodium sulfate
  7. filtrationfiltered
  8. concentrationconcentrated under reduced pressure
  9. dissolutionThe residue was dissolved in DCM (1 mL) at room temperature
  10. additioncharged with TFA (1 mL)
  11. stirringThe mixture was stirred 3 h, whereupon the volatiles
  12. customwere removed via a stream of nitrogen
  13. customthe crude mixture was purified via preparative HPLC (Waters Sunfire column 5u, 100 A°, 19×100 mm, 20-100% Solvent B, (Solvent A (90% water, 10% methanol, 0.1% TFA), Solvent B (10% water, 90% methanol, 0.1% TFA), 10 min gradient, 10 minute run, 25 mL/min))

Quellen und Nachweise

ORD-Eintrag
ord-fc447e0cce384552b3ecf24a8b3c6750
Quelldatensatz
uspto-grants-2013_03
Patentnummer
US08389527B2

Verknüpfte Notizen

Wird geladen…